125I生产工艺研究进展与展望  

125I Production Technology:Current Status and Future Perspective

作　　者：李波[1,2] 罗宁 曾俊杰[1,2] 吴建荣 贾致军[1,2] 王磊 孙志中 陈云明 张劲松[1,2] LI Bo;LUO Ning;ZENG Junjie;WU Jianrong;JIA Zhijun;WANG Lei;SUN Zhizhong;CHEN Yunming;ZHANG Jingsong(Nuclear Power Institute of China,Chengdu 610213,China;Radioisotope Engineering Technology Research Center of Sichuan,Chengdu 610213,China)

机构地区：[1]中国核动力研究设计院,成都610213 [2]四川省放射性同位素工程技术研究中心,成都610213

出　　处：《同位素》2020年第6期366-373,共8页Journal of Isotopes

摘　　要：125I是一种重要的医用放射性核素,由于其半衰期较长(T1/2=59.4 d),γ射线能量低、无β辐射,对人体组织产生的辐射损伤小等优点,使其在生物医学、放射免疫体外诊断和近距离植入治疗肿瘤等方面得到了广泛应用。本文简要介绍125I的生产原理、国内外生产工艺研究现状、国内市场需求,并展望125I的生产前景。Iodine-125(125I)is one of the most attractive and significant radionuclide that is widely used in biomedical,radioimmunoassay in vitro diagnosis and brachytherapy for tumors owing to its favorable nuclear characteristics,including low energy X-ray,noβ-ray,less radiation damage.In this paper,the process and current status of 125I production technology,demand of domestic market and the prospect of 125I were briefly introduced.

关 键 词：125I 反应堆 放射性核素 近距离植入治疗 肿瘤 

分 类 号：TL921[核科学技术—核燃料循环与材料]